Article
Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.
Genetics in medicine : official journal of the American College of Medical Genetics - 1 Nov 2022
Wenger Tara L, Ganti Sheila, Bull Catherine, Lutsky Erika, Bennett James T, Zenner Kaitlyn, Jensen Dana M, Dmyterko Victoria, Mercan Ezgi, Shivaram Giri M, Friedman Seth D, Bindschadler Michael, Drusin Madeleine, Perkins Jonathan N, Kong Ada, Bly Randall A, Dahl John P, Bonilla-Velez Juliana, Perkins Jonathan A
Abstract excerpt
PURPOSE: PIK3CA-related overgrowth spectrum (PROS) conditions of the head and neck are treatment challenges. Traditionally, these conditions require multiple invasive interventions, with incomplete malformation removal, disfigurement, and possible dysfunction. Use of the PI3K inhibitor alpelisib, previously shown to be effective in PROS, has not been reported in PIK3CA-associated head and neck lymphatic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.